Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury

Completed · Phase 2 · Has a placebo group

Conditions studied: Hemorrhage, Shock, Wounds and Injuries

In brief

The purpose of this study is to evaluate the effects of TXA on the immune system, its pharmacokinetics, as well as safety and efficacy in severely injured trauma patients.

Key facts

Study ID

NCT02535949

Run by

Washington University School of Medicine

People needed

150

Starts

2016-02-01

Expected to finish

2017-07-07

Last updated by the study team

2021-08-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with traumatic injury that are ordered to receive at least 1 blood product and/or
• Patients admitted to the Emergency Department with a traumatic injury and require immediate transfer to the operating room to control the bleeding
• Able to receive the study drug within 2 hours from estimated time of injury **Please note that in circumstances where the patient initially met inclusion/exclusion criteria (i.e. received blood products in the ED before a full evaluation of their injuries is complete) but is later found to only have a soft tissue involved injury or does not have a traumatic bleeding source), the Investigator may determine that the patient should not be randomized into the trial and the patient should be considered a screen failure

You may not qualify if…

• Patients known to be < 18 years of age
• Suspected Acute MI or stroke(thromboembolic and/or hemorrhagic) on admission
• Known inherited coagulation disorders
• Known history of thromboembolic events (DVT, PE, MI, Stroke)
• Please note that past medical history of hemorrhagic stroke is permitted, but not current admission with hemorrhagic stroke
• Known history of seizures and/or seizure after injury/on admission related to this hospitalization
• Suspected or known pregnancy
• Known to be lactating
• Suspected or known prisoners
• Futile care
• Known current state of immunosuppression (i.e. on high dose steroids, chemotherapeutics, etc.)
• Unknown estimated time of injury 12). Patients wearing an "Opt Out" TAMPITI Study bracelet 13). Known presence of subarachnoid hemorrhage.
• ) Isolated injuries to hands and/or feet (distal) 15.) Administration of antifibrinolytics pre-hospital and/or during this ED admission prior to enrollment

Where it is running

• Barnes Jewish Hospital — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.